PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

This week we welcomed the federal government's announcement that a respiratory syncytial virus (RSV) vaccine for pregnant women would be included on ...

For comparison, Pfizer reported yesterday that Abrysvo made full-year sales of $890 million, which - while respectable - were well below its competitor. However, it brought in $515 million in the ...

The regulator is due to make a decision on Pfizer’s rival vaccine Abrysvo later this month. Getting FDA approval is just the first hurdle for the two vaccines, however. Assuming they are both ...

With respect t NEW YORK, October 22, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine ...